Breast Cancer Research and Treatment **44**: 279, 1997.
© 1997 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 44

Adami F 185
Adhikarakunnathu S 47
Allen K 135
Allred DC 65
Antonelli G 255
Armitage JO 115
Arnesson L-G 39
Ashley SE 65

Banzi C 185
Bardy P 153
Bellamy C 123
Bergerat JP 261
Biasi S 255
Biganzoli E 167
Bilbao G 93
Bonadonna G 255
Bontenbal M 179
Boracchi P 167
Brueggemeir RW 57
Bruno S 167
Buchanan RB 201
Burak WE Jr 57

Caldéroli H 261
Cameron DA 123
Cantor A 135
Chen Z 217
Chetty U 123
Conneally E 153
Coradini D 167
Cox CE 135
Criscuolo M 185
Crouse DA 115
Crump M 201
Curiel DT 93

De Boer G 201,211
De Candis A 255
Demicheli R 255
Dickson RB 1
Dixon JM 123
Dotzlaw H 145
Dowsett M 65

Eaves CJ 153
Ekena K 23
Emerman JT 153

Faaland CA 47
Farrar WB 57
Fernando IN 65
Forbes JN 201
Frassoldati A 185
Fukao A 225
Fuqua SAW 145

Gairard B 261
Garbagnati F 255
Giacobone A 255
Goss G 153
Greenberg H 135
Gröntoft O 39
Grushcow J 93
Gueriec N 261

Hanby A 123
Hatschek T 39
Herman ME 23
Hirvikoski PP 269
Hisamichi S 225
Humphries RK 153

Ingle JN 201

Johansson RT 269
Joshi SS 115
Jung W-H 193
Juriskay S 83

Kabuto M 235
Katzenellenbogen BS 23
Kawakami N 75
Keen JC 123
Kessinger A 115
Kett K 83
Kim YT 217
Koo Y 193
Kumar NB 135
Kumpulainen EJ 269

Laffranchi A 255
Lansdorp PM 153
Lee H-D 193
Lenoir G 275
Lyman GH 135
Lynch HT 275

Makris A 65
Mann SL 115
Marcellin L 261
Marcus JN 275
Mariani L 167
Marubini E 167
McInerney EM 23
Meakin JW 201,211
Miller EP 123
Miller WR 123
Minami Y 225
Molteni A 217
Montano MM 23
Murphy LC 145

Nagata C 235
Nagata C 75
Narod SA 275
Nass SJ 1

Obdeijn AIM 179
Oberling F 261
Oh K-K 193
Ohuchi N 225
Ormerod MG 65
Osborne CK 65
Oudkerk M 179

Page DL 275
Paterson AHG 211
Piccinini L 185
Pilotti S 167
Pirrucello SJ 243
Powles TJ 65
Pritchard KI 201,211

Quinn AL 57

Renaud R 261
Rilke F 167
Rosenfeld M 93
Ruppert JM 93

Sawka CA 201,211
Serova O 275
Shah S 135
Sharp JG 115
Shaw-Bruha CM 243
Shelley W 201,211
Shimizu H 235
Shimizu H 75
Shull JD 243
Silingardi V 185
Silvestrini R 167
Small W Jr 217
Smeds S 39
Strong TV 93
Suh C-O 193
Sutherland DJA 211
Szabó I 83

Takatsuka N 235
Taylor JM 217
Terenziani 255
Thomas T 47
Thomas TJ 47
Tilanus-Linthorst MMA 179
Titley JC 65
Tonin P 275
Trott PA 65

Vaughan WP 115
Veronesi U 167

Wang M 145
Ward WF 217
Watson P 275
Weisenburger DD 115
Wilk A 261
Wright M 93

Yoon D-S 193

Zambetti M 255
Zucali R 167

Breast Cancer Research and Treatment **44**: 281-284, 1997.
© 1997 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 44

adjuvant therapy
  hepatic toxicity of CMF/CNF reversed by tamoxifen 269-274
age
  different risk factors for different age at diagnosis, Japan 225-233
alternative splicing
  see splicing
amplification
  c-Myc in breast tumorigenesis 1-22
androgens
  aromatase required for induction of pS2 in MCF-7 cells 57-64
antiestrogens
  mechanisms of action and resistance — review 23-38
  see also tamoxifen
antihypertensive agents
  captopril inhibits growth and ER, induces PgR 217-224
apoptosis
  c-Myc in breast tumorigenesis 1-22
apoptosis
  higher initial Bcl-2 and greater tamoxifen response 123-133
  increase with primary chemotherapy 185-192
aromatase
  required for androgen induction of pS2 in MCF-7 cells 57-64

Bcl-2
  higher initial Bcl-2 and greater tamoxifen response 123-133
biomarkers
  changes induced by primary chemotherapy 185-192
bone marrow cultures
  increased progenitor cell maintenance in the presence of breast cancer cells 115-121
BRCA2
  distinctive breast cancer phenotype (vs. BRCA1) 275-277
breast conserving therapy
  in Korea — vs. mastectomy 193-199

CD44
  variant expression (by RT-PCR) and metastasis 261-268
cell cycle
  c-Myc in breast tumorigenesis 1-22
chemotherapy
  FU 5-day infusion plus vinorelbine — response in pretreated patients 255-260
  hepatic toxicity of adjuvant CMF/CNF reversed by tamoxifen 269-274
  molecular — review of gene therapy strategies 93-114
  primary — induced biomarker and apoptosis changes 185-192
co-regulators
  in antiestrogen action, resistance at ER 23-38
contralateral breast cancer
  neural network modeling of prognostic factors 167-178
cyclins
  tyrphostin suppression of cyclin B1, $p34^{cdc2}$ activity 47-56
cytologic evaluation
  successful determination of seven prognostic factors on fine needle aspirates 65-74

detection
  of occult primaries with MRI 179-182
drug resistance
  antiestrogen mechanisms of action and resistance 23-38

endocrine therapy
  antiestrogen mechanisms and resistance — review 23-38

meta-analysis of tamoxifen vs. ovarian ablation in first line 201-210
tamoxifen vs. ovarian ablation in first line — randomized trial 211-215
see also tamoxifen
epithelial cells
normal human breast — retroviral gene transfer 153-165
estrogen receptor
concordance between EIA on tumor and ICA on fine needle aspirates 65-74
in prognostic models for contralateral breast cancer 167-178
in mechanisms of antiestrogen action and resistance 23-38
point mutation leading to a 69-nucleotide insert 145-151
reduced by the antihypertensive captopril 217-224
estrogens
aromatase required for estrogenic activity of androgens in MCF-7 cells 57-64

familial breast cancer
distinctive phenotype in BRCA2 (vs. BRCA1) families 275-277
family history
and risk in younger Japanese women 225-233
fine needle aspirates
successful determination of seven prognostic factors 65-74
flow cytometry
in retroviral vector expression after gene transfer to normal breast cells 153-165
on fine needle aspirate material 65-74
fluorouracil
five-day infusion plus vinorelbine — response in pretreated patients 255-260

gene therapy
strategies in breast cancer — review 93-114
gene transfer
retroviral vector for normal human breast epithelial cells 153-165

hematopoietic progenitor cells
increased maintenance in marrow cultures in the presence of breast cancer cells 115-121
hereditary breast cancer
distinctive phenotype in BRCA2 (vs. BRCA1) families 275-277
histologic grade
in small screen-detected breast cancers 39-46
histone H1 phosphorylation
suppression by tyrphostin-47 47-56
Hs578T human breast cancer cells
captopril (antihypertensive) inhibits growth, induces PgR, in breast cancer cells 217-224

immunocytochemistry
successful determination of seven prognostic factors on fine needle aspirates 65-74
immunotherapy
genetic — review of gene therapy strategies 93-114
incidence
trends vs. risk factors in Japan 75-82

Japan
risk factors in screen-detected breast cancer 225-233
steroid hormone level correlations with alcohol, height, reproductive factors 235-241
trends in breast cancer incidence and risk factors 75-82

Ki-S1
reduced in tamoxifen responders 123-133

lactation
for the last child — reduced breast cancer risk (Japan) 225-233
loss of heterozygosity (LOH)
gene therapy strategies in breast cancer — review 93-114

magnetic resonance imaging (MRI)
detection of occult primaries with axillary metastases 179-182
marrow
see bone marrow
mastectomy
equal results with breast conserving therapy in Korea 193-199
MCF-7 human breast cancer cells
tyrphostin suppression of cyclin B1, $p34^{cdc2}$ activity 47-56

McGuire Lecture
antiestrogen mechanisms and resistance 23-38
meta-analysis
tamoxifen vs. ovarian ablation in first line therapy 201-210
metastasis
and CD44 variant expression by RT-PCR 261-268
mutation compensation
gene therapy strategies in breast cancer — review 93-114
myc oncogene
in breast tumorigenesis — review 1-22

neural networks (computer)
modeling of prognostic factors for contralateral breast cancer 167-178

occult primary
detection with MRI 179-182
oncogenes
c-*myc* in breast tumorigenesis 1-22
gene therapy strategies in breast cancer — review 93-114
oophorectomy
vs. tamoxifen in first line — randomized trial 211-215
vs. tamoxifen in first line — meta-analysis 201-210
overexpression
c-Myc in breast tumorigenesis 1-22

parity
and risk in older Japanese women 225-233
pathology
histologic grading in screened breast cancers ≤10mm 39-46
progenitor cells
increased maintenance in marrow cultures in the presence of breast cancer cells 115-121
progesterone receptor
in prognostic models for contralateral breast cancer 167-178
induced by the antihypertensive captopril 217-224
prognostic factors
CD44 variant expression (by RT-PCR) and metastasis 261-268
for contralateral breast cancer — neural network modeling 167-178
histologic grading in small screen-detected breast cancers 39-46
prognostic factors *cont.*
successful determination of ER, PgR, p53, Ki67, bcl-2, S-phase, and ploidy on fine needle aspirates 65-74
prolactin gene
promoter choice and alternative splicing in normal and malignant breast cells 243-253
proto-oncogenes
see oncogenes
pS2
aromatase required for induction by androgens in MCF-7 cells 57-64

resistance
see drug resistance
retrovirus
vector in gene transfer to normal breast epithelial cells 153-165
risk factors
alcohol, height, reproductive factor correlations with steroid hormone levels in Japan 235-241
and breast cancer incidence trends in Japan 75-82
in screen-detected breast cancer in Japan 225-233

screening
risk factors in screen-detected breast cancer at different ages in Japan 225-233
signal transduction
tyrphostin-47 suppression of cyclin B1 47-56
splicing of mRNA
alternative splicing in prolactin gene expression in breast cells 243-253
estrogen receptor point mutation leading to a 69-nucleotide insert 145-151
statistical analysis
neural network modeling of prognostic factors for contralateral breast cancer 167-178
stem cells
increased maintenance in marrow cultures in the presence of breast cancer cells 115-121

steroids
correlations with alcohol, height, reproductive risk factors in Japan 235-241
in urine and serum — few differences in breast cancer vs. controls 83-89
surgery
equal results for mastectomy and breast conserving therapy in Korea 193-199

T47D human breast cancer cells
captopril (antihypertensive) inhibits growth and ER, induces PgR, in breast cancer cells 217-224
tamoxifen
higher initial Bcl-2 and greater response 123-133
mechanisms of action and resistance — review 23-38
no evidence for weight gain with treatment 135-143
reversal of hepatic toxicity of adjuvant CMF/CNF 269-274
vs. ovarian ablation in first line — meta-analysis 201-210
vs. ovarian ablation in first line — randomized trial 211-215
topoisomerase II
see Ki-S1
transcription regulation
estrogen receptor and antiestrogens in modes of nuclear gene activation 23-38
transcription regulation *cont.*
via Myc, Max, and Mad 1-22
transgenic mice
c-Myc models and breast tumorigenesis 1-22
tumor suppressor genes
gene therapy strategies in breast cancer — review 93-114
tyrphostins
3,4-dihydroxy-α-cyanocinnamamide (tyrphostin-47) 47-56
cyclin B1 suppression and B1/$p34^{cdc2}$ inihibition 47-56

unknown primary
detection with MRI 179-182
urinary steroids
few differences in breast cancer vs. controls 83-89

vinorelbine
with five-day infusion fluorouracil — response in pretreated patients 255-260

weight gain
no correlation with tamoxifen treatment or outcome 135-143